Evidence map›Paper›PMID 31312283›Full record

ArticleWorld journal of oncology2019

Acute Myeloid Leukemia Acquiring Promyelocytic Leukemia-Retinoic Acid Receptor Alpha at Relapse.

Varsha Gupta, Mohammed Shariff, Ravneet Bajwa, Ishan Patel, Hashem A Ayyad, Michael J Levitt, Peter J Mencel, Mohammad A Hossain

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Varsha GuptaDepartment of Medicine, Jersey Shore University Medical Center, Hackensack Meridian Health, Neptune, NJ, USA.
Mohammed ShariffDepartment of Medicine, Jersey Shore University Medical Center, Hackensack Meridian Health, Neptune, NJ, USA.
Ravneet BajwaDepartment of Medicine, Jersey Shore University Medical Center, Hackensack Meridian Health, Neptune, NJ, USA.
Ishan PatelDepartment of Medicine, Jersey Shore University Medical Center, Hackensack Meridian Health, Neptune, NJ, USA.
Hashem A AyyadDepartment of Pathology, Jersey shore University Medical Center, Neptune, NJ, USA.
Michael J LevittDepartment of Medicine, Jersey Shore University Medical Center, Hackensack Meridian Health, Neptune, NJ, USA.
Peter J MencelDepartment of Medicine, Jersey Shore University Medical Center, Hackensack Meridian Health, Neptune, NJ, USA.
Mohammad A HossainDepartment of Medicine, Jersey Shore University Medical Center, Hackensack Meridian Health, Neptune, NJ, USA.
Jersey Shore University Medical Center · USHackensack Meridian Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute promyelocytic leukemia (APL) is identified as the M3 subtype of acute myeloid leukemia (AML). APL is presently one of the most curable leukemias. We describe here a rare case of APL who presented as a relapsed disease after 1 year of chemotherapy for AML. The patient lacked t(15;17) at the initial presentation but was present later at the time of relapse. The patient attained a complete remission following treatment with all-trans retinoic acid (ATRA) and arsenic trioxide-based therapy. We discuss the possible mechanism behind secondary acquisition of promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA) at relapse of AML. We also briefly discuss the clinical features, diagnosis and treatment of APL.

Indexed as

Acute myeloid leukemiaAcute promyelocytic leukemiaAll-trans retinoic acid

Identifiers

PMID31312283
PMCPMC6615911
OpenAlexW2955297231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.